Drug Trial Radar · NCT07289035
Early Study on Tamoxifen Safety/Tolerability in Cystic Fibrosis Patients Unable to Use CFTR Modulators.
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
35
Planned (sponsor's estimate)
Start
Jan 22, 2026
Primary completion
Jun 30, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Azienda Ospedaliera Universitaria Integrata VeronaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the safety and tolerability of TMX in adults patients with cystic fibrosis who do not have mutations currently eligible for therapy with modulator drugs. The main questions it aims to answer is: . What medical problems do participants have when taking drug TMX? Participants will: * Take drug TMX every day for 6 months * Visit the clinic once every 28 days for checkups and tests
Conditions
- Cystic Fibrosis - Complete
Interventions
Tamoxifen Citrate 20Mg TabDrug
One tablet per day (20 mg/day), in the morning.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0Time frame: Calculating between baseline and week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
UOC Fibrosi Cistica - AOUI Verona
Verona, Veneto, Italy · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.